Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines

Cell Cycle

Volumn 9, Issue 24, 2010, Pages 4900-4907

  Cooley, Anne ^a   Zelivianski, Stanislav ^a   Jeruss, Jacqueline S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; CDK2; Cyclin E; Smad3; TGF

Indexed keywords

CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; LUCIFERASE; MYC PROTEIN; PROTEIN P15; PROTEIN P21; SMAD3 PROTEIN; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

EID: 78650399203     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.24.14158     Document Type: Article

References (34)

1. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Downregulation of activin, activin receptors and Smads in high-grade breast cancer. Cancer Res 2003; 63:3783-90.
2. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005; 65:7968-75.
3. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGFbeta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82:85-91.
4. Feng XH, Liang YY, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGFbeta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 2002; 9:133-43.
5. Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002; 191:1-16.
6. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16:1094-9.
7. Park C, Lee I, Kang WK. E2F-1 is a critical modulator of cellular senescence in human cancer. Int J Mol Med 2006; 17:715-20.
8. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem 2002; 277:854-61.
9. Yue J, Mulder KM. Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 2001; 91:1-34.
10. Jeruss JS, Santiago JY, Woodruff TK. Localization of activin and inhibin subunits, receptors and SMADs in the mouse mammary gland. Mol Cell Endocrinol 2003; 203:185-96.
11. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, et al. Determinants of specificity in TGFbeta signal transduction. Genes Dev 1998; 12:2144-52.
12. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-31.
13. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75.
14. Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomaki K, Heikkila P, et al. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 2008; 14:1976-83.
15. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037-44.
16. 1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002; 33:877-83.
17. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27 and antiestrogens in breast cancer. Cancer Res 2004; 64:3198-208.
18. Enders GH. Cyclins in breast cancer: too much of a good thing. Breast Cancer Res 2002; 4:145-7.
19. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997; 17:453-9.
20. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 2009; 115:651-9.
21. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res 2004; 6:188-91.
22. Sgambato A, Camerini A, Collecchi P, Graziani C, Bevilacqua G, Capodanno A, et al. Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci 2009; 100:1026-33.
23. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996; 93:15215-20.
24. Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D, et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 2006; 25:7245-59.
25. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14:1669-79.
26. Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res 2006; 66:7948-56.
27. Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest 2006; 24:581-7.
28. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 2007; 67:7212-22.
29. Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, et al. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci USA 2001; 98:13138-43.
30. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 2005; 280:15148-57.
31. Wadler S. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat 2001; 4:347-67.
32. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29:4018-32.
33. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45.
34. Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, et al. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer 102:342-50.